Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries
ClinicalTrials.gov Identifier:
NCT00605215
First received: January 8, 2008
Last updated: August 16, 2013
Last verified: August 2013
  Purpose

The study aims to compare the effect of daily oral treatment of laquinimod capsules 0.6 mg with the effect of placebo capsules (capsules that contain no active medication) as well as with the effect of an existing MS injectable drug: Interferon β-1a (Avonex®).


Condition Intervention Phase
Multiple Sclerosis
Drug: laquinimod
Drug: placebo
Drug: Interferon β-1a (Avonex®)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With RRMS to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-blind Design and a Reference Arm of Interferon β-1a (Avonex®) in a Rater-blinded Design.

Resource links provided by NLM:


Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Assess efficacy, as measured by number of confirmed relapses [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Accumulation of physical disability [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Measured by the time to confirmed progression of Expanded Disability Status Scale (EDSS). A confirmed progression of EDSS is defined as a 1 point increase from baseline on EDSS score if baseline EDSS was between 0 and 5.0, or a 0.5 point increase if baseline EDSS was 5.5, confirmed 3 months later.

  • The cumulative number of enhancing lesions on T1-weighted images [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Images taken at months 12 and 18

  • General health status [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Using Short Form (SF-36) survey subject-reported questionnaire obtained at month 0 and every 6 months thereafter.

  • The cumulative number of new hypointense lesions on enhanced T1 scans [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Taken at months 12 and 18


Enrollment: 1331
Study Start Date: April 2008
Study Completion Date: December 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Laquinimod
0.6 mg Laquinimod oral once daily
Drug: laquinimod
0.6 mg oral once daily for 24 months
Placebo Comparator: Placebo
oral placebo once daily
Drug: placebo
oral placebo once daily for 24 months
Active Comparator: Interferon
Interferon β-1a (Avonex®) 30 mcg IM once weekly
Drug: Interferon β-1a (Avonex®)
Interferon β-1a (Avonex®) 30 mcg IM once weekly for 24 months

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects must have a confirmed and documented MS diagnosis as defined by the Revised McDonald criteria [Ann Neurol 2005: 58:840-846], with a relapsing-remitting disease course.
  2. Subjects must be ambulatory with converted Kurtzke EDSS score of 0-5.5.
  3. Subjects must be in a stable neurological condition between screening (month -1) and baseline visits (month 0).
  4. Subjects must have had experienced one of the following:
  5. At least one documented relapse in the 12 months prior to screening
  6. At least two documented relapses in the 24 months prior to screening
  7. One documented relapse between 12 and 24 months prior to screening with at least one documented T1-Gd enhancing lesion in an MRI performed within 12 months prior to screening.
  8. Subjects must be between 18 and 55 years of age, inclusive.
  9. Subjects must have disease duration of at least 6 months (from first symptom) prior to screening.
  10. Women of child-bearing potential must practice 2 acceptable methods of birth control [acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy or double-barrier method (condom or diaphragm with spermicide)].
  11. Subjects must be willing and able to comply with the protocol requirements for the duration of the study.

    a. Exclusion Criteria:

  12. An onset of relapse or any treatment with corticosteroids (intravenous [iv], intramuscular [im] and/or per os [po]) or ACTH between month -1 (screening) and 0 (baseline).
  13. Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to screening.
  14. Use of immunosuppressive (including Mitoxantrone (Novantrone®) or cytotoxic agents within 6 months prior to the screening visit.
  15. Previous use of either of the following: natalizumab (Tysabri®), cladribine or laquinimod.
  16. Previous treatment with glatiramer acetate (Copaxone®) or IVIG within 3 months prior to screening visit.
  17. Previous treatment with Interferon beta-1a (Avonex® or Rebif®) or Interferon beta-1b (Betaseron®).
  18. Systemic corticosteroid treatment of ≥30 consecutive days duration within 2 months prior to screening visit.
  19. Previous total body irradiation or total lymphoid irradiation.
  20. Previous stem-cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation.
  21. A known history of tuberculosis.
  22. Acute infection 2 weeks prior to baseline visit.
  23. Major trauma or surgery 2 weeks prior to baseline visit.
  24. A history of vascular thrombosis (excluding catheter-site superficial venous thrombophlebitis).
  25. A carrier state of factor V Leiden mutation (either homo- or heterozygous) by history or as disclosed at screening.
  26. Positive screening test for Hepatitis B surface antigen, Hepatitis C antibody, or HIV antibody as disclosed at screening visit.
  27. Use of potent inhibitors of CYP3A4 within 2 weeks prior to baseline visit (see detailed list of drugs in protocol) (1 month for fluoxetine).
  28. Use of amiodarone within 2 years prior to screening visit.
  29. Pregnancy or breastfeeding.
  30. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical examinations, ECG, laboratory tests or chest X-ray. Such conditions may include:

    • A cardiovascular or pulmonary disorder that cannot be well-controlled by standard treatment permitted by the study protocol.
    • A gastrointestinal disorder that may affect the absorption of study medication.
    • Renal, metabolic, endocrinological or hematological diseases.
    • Any form of chronic liver disease, including known non-alcoholic steatohepatitis.
    • A ≥2xULN serum elevation of either of the following at screening: ALT, AST or direct bilirubin.
    • A QTc interval (obtained from either two ECG recordings at screening or from the mean value calculated from three measurements at baseline visit) which is ≥450msec.
    • A family history of Long-QT syndrome.
    • A history of drug and/or alcohol abuse.
    • Major psychiatric disorder.
    • A history of a convulsive disorder.
    • Known hypersensitivity to either of the following: mannitol, meglumine or sodium stearyl fumarate.
    • Known hypersensitivity that would preclude administration of laquinimod.
  31. The subject's inability to give informed consent, or to complete the study, or if the subject is considered by the investigator to be, for any reason, an unsuitable candidate for this study.
  32. A known history of sensitivity to Gadolinium.
  33. Inability to successfully undergo MRI scanning.
  34. A known history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation of Avonex®.

Exclusion Criteria:

  1. Subjects who suffer from any form of progressive MS
  2. Any condition which the investigator feels may interfere with participation in the study
  3. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation
  4. Subjects who received any investigational medication, immunosuppressives or cytotoxic agents within 6 months prior to screening
  5. Previous treatment with immunomodulators within two months prior to screening
  6. Pregnancy or breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00605215

  Show 140 Study Locations
Sponsors and Collaborators
Teva Pharmaceutical Industries
Investigators
Principal Investigator: Timothy L. Vollmer St. Joseph's Hospital & Medical Center
  More Information

No publications provided

Responsible Party: Teva Pharmaceutical Industries
ClinicalTrials.gov Identifier: NCT00605215     History of Changes
Other Study ID Numbers: MS-LAQ-302, EUDRACT 2007-005450-23
Study First Received: January 8, 2008
Last Updated: August 16, 2013
Health Authority: United States: Food and Drug Administration
Austria : Federal Ministry for Labour, Health, and Social Affairs
Bulgaria: Bulgarian Drug Agency
Canada: Health Canada
Czech Republic: State Institute for Drug Control
Estonia: The State Agency of Medicine
European Union: European Medicines Agency
France: Ministry of Health
Georgia: Ministry of Health
Germany: Ministry of Health
Hungary: National Institute of Pharmacy
Israel: Ministry of Health
Italy: Ministry of Health
Latvia: State Agency of Medicines
Lithuania: State Medicine Control Agency - Ministry of Health
Netherlands: Medicines Evaluation Board (MEB)
Poland: Ministry of Health
Romania: Ministry of Public Health
Russia: Ministry of Health of the Russian Federation
Bulgaria: Ministry of Health
Spain: Ministry of Health
Sweden: Medical Products Agency
Turkey: Ministry of Health
Ukraine: Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Multiple Sclerosis
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Interferon beta 1a
Interferon-beta
Interferons
Adjuvants, Immunologic
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014